Skip to main content

Table 4 Qualitative evaluation of the temporal changes in IBA1 and GFAP immunostaining after MPTP treatment

From: The CD200R1 microglial inhibitory receptor as a therapeutic target in the MPTP model of Parkinson’s disease

   Time after the last injection of MPTP
   2 h 1 day 2 days 4 days 7 days
Striatum IBA1 + +++ +++ + +
  GFAP 0 + +++ +++ ++
SNpc IBA1 0 ++ +++ +++ ++
  GFAP 0 + +++ +++ ++
  1. Changes in IBA1 and GFAP immunolabelling vs. control mice: 0 = similar to control; + = some cells, ++ = moderate number of cells and +++ = many cells with hypertrophied morphology and intensified IBA1 or GFAP staining